What Cytrellis Biosystems does

Cytrellis Biosystems, Inc. is a private, venture-backed medical technology company headquartered in Woburn, Massachusetts, that develops and commercializes aesthetic devices. Its core product, the ellacor® System with Micro-Coring® Technology, is an FDA-cleared platform that uses proprietary hollow needles to mechanically extract micro-cores of dermal and epidermal tissue while stimulating natural collagen and elastin production. The mechanism is positioned as the only nonsurgical treatment that physically removes excess skin without thermal energy or surgery; the November 2025 FDA clearance extends use to full-body resurfacing beyond the original mid and lower face indication. The company launched an upgraded ellacor 2.0 platform in January 2025 claiming a 35% reduction in treatment time and 60% faster healing relative to its predecessor.

The company monetizes through direct sale of the ellacor capital system to aesthetic medical practitioners (plastic surgeons, dermatologists, and aesthetic physicians) and through associated per-procedure consumables performed in-office. Go-to-market is enterprise field sales to individual practices, supported by physician training through a dedicated medical portal (aesthetics-central.com/info/cytrellis) and consumer-facing marketing via ellacor.com and brand social channels. As of early 2023 the company had delivered its 100th system and completed its 1,000th procedure; commercial scope has since expanded into Canada and Saudi Arabia following regulatory approvals in those jurisdictions, with the first Canadian launch at Lawrence Park Plastic Surgery in Toronto in March 2026.

Cytrellis is led by President and CEO Denise Dajles, PhD, with an operating team drawn from prior roles at Sientra, Merz Aesthetics, Allergan, and Establishment Labs, and a board chaired by John McDonough (former founding CEO of T2 Biosystems) and including Keith L. Crandell of ARCH Venture Partners as a director. Co-founders Rox Anderson, MD (Harvard/MIT, co-inventor of fractional laser treatment) and William Austen, Jr., MD (Chief of Plastic and Reconstructive Surgery at Mass General) anchor the clinical and scientific foundation. The technology is protected by at least eight issued U.S. patents covering the Micro-Coring method and device architecture.

Name

Cytrellis Biosystems

Legal name

Cytrellis Biosystems, Inc.

Website

https://cytrellis.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

Cytrellis Biosystems is a private medical technology company that develops and commercializes the FDA-cleared ellacor system with proprietary Micro-Coring Technology for minimally invasive, nonsurgical skin removal, selling directly to plastic surgeons, dermatologists, and aesthetic physicians in the United States, Canada, and Saudi Arabia.

Ownership category

akta.pro rank

Product category

Aesthetic Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Skincare Devices (Cleansing Brushes, Microcurrent, LED, Dermaplaning) (CRABAKAI)

Keywords

• Medical aesthetic devices
• Minimally invasive skin removal
• Micro-coring technology
• Dermatology medical devices
• Nonsurgical skin tightening

Headquarters

HQ city

Woburn

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device and Consumables Sales: Cytrellis sells the ellacor system (hardware) and associated consumables to aesthetic medical practitioners. Procedures are performed in-office by trained physicians. Revenue is generated through device placement and per-procedure consumable usage.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Core offering

Cytrellis develops and commercializes the ellacor® System with Micro-Coring® Technology, an FDA-cleared minimally invasive medical device that uses proprietary hollow needles to extract micro-cores of dermal and epidermal tissue while stimulating natural collagen and elastin production. The system is the only nonsurgical treatment that removes excess skin without surgery or thermal injury and is indicated for moderate to severe wrinkles in the mid to lower face in adults 22+ with Fitzpatrick Skin Types I-IV. The company sells the device and associated consumables directly to aesthetic medical professionals for in-office use.

Product overview

Cytrellis Biosystems is a medical technology company dedicated to developing and commercializing first-in-class aesthetic devices. The company's primary product is the ellacor® System with Micro-Coring® Technology, an FDA-cleared system that removes sagging skin on the micro-scale using proprietary hollow needles. The core ellacor system treats moderate to severe wrinkles in the mid and lower face, while ellacor 2.0 represents a next-generation upgrade with improved treatment time and healing. The company operates ellacor.com as a patient-facing portal and an aesthetics-central medical portal for healthcare providers. Cytrellis holds multiple U.S. patents protecting the Micro-Coring Technology and has received regulatory approvals in the U.S., Canada, and Saudi Arabia.

Differentiator

Problem solved

Functional benefit

Brands

• ellacor: FDA-cleared Micro-Coring technology system for minimally invasive skin removal treatment of moderate to severe wrinkles in mid to lower face. Product line includes ellacor 2.0 with improved treatment time and healing.
• ellacor 2.0

Products and services

• ellacor® System with Micro-Coring® Technology FDA-cleared minimally invasive skin removal system that uses proprietary hollow needles to extract micro-cores of dermal and epidermal tissue while stimulating natural collagen and elastin production. Indicated for treatment of moderate to severe wrinkles in the mid and lower face in adults aged 22+ with Fitzpatrick skin types I-IV, and used by aesthetic medical professionals (plastic surgeons, dermatologists) for in-office procedures.
• ellacor® 2.0 Next-generation upgrade of the ellacor® System with Micro-Coring® Technology optimized for enhanced patient and provider experience, delivering 35% reduction in treatment time and 60% faster healing compared to the original system. Sold to aesthetic medical professionals for in-office use.

Quantifiable outcome

• 35% reduction in treatment time with ellacor 2.0
• +3 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Lawrence Park Plastic SurgerycoreChannel Partner/ Reseller/ Distributor · 5 March 2026Lawrence Park Plastic Surgery in Toronto is the first clinic in Canada to offer the ellacor system with Micro-Coring technology. Dr. Mathew Plant became the first plastic surgeon in Canada to perform the procedure. The launch marks Cytrellis' expansion into the Canadian market, positioning the technology as an alternative between non-invasive treatments and surgery for Canadian patients seeking skin restoration.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Lumenis (Boston Scientific): Lumenis (acquired by Boston Scientific) manufactures the ResurFX and M22 platforms for fractional skin resurfacing, plus a broad surgical laser portfolio. Its aesthetic platforms compete with ellacor for skin rejuvenation procedure volumes in dermatology and plastic surgery practices.
• Candela Medical: Candela (acquired by Apax Partners) provides a broad portfolio of aesthetic energy-based devices (GentleLase, Vbeam, Nordlys, Profound) used by plastic surgeons and dermatologists. As a larger established player, it competes for the same practice capital and patient indications across multiple categories.
• Allergan Aesthetics (AbbVie): AbbVie's Allergan Aesthetics division markets CoolSculpting and a portfolio of facial aesthetics products to plastic surgeons and dermatologists. As the largest aesthetics company globally, it sets competitive benchmarks and bundles offerings that compete for the same practice capital as ellacor.

Direct peers

• Cutera, Inc. Cutera markets energy-based aesthetic devices (excel V+, truSculpt, Secret RF) to plastic surgeons and dermatologists for skin rejuvenation and body contouring. Its Secret RF microneedling platform and broader device portfolio compete for the same practice capital budget and patient indications as ellacor.
• InMode Ltd. InMode develops minimally invasive and non-invasive aesthetic medical devices (BodyTite, Morpheus8, FaceTight) sold to plastic surgeons and dermatologists - the same physician channel Cytrellis targets. Its Morpheus8 microneedling RF platform directly competes with ellacor's skin remodeling proposition.
• Cynosure (Hologic): Cynosure is a leading developer of light-based and RF aesthetic systems (PicoSure, TempSure, Potenza) sold to medical aesthetic practices. Its Potenza microneedling RF device competes head-to-head with ellacor's skin remodeling value proposition.
• BTL Industries: BTL Industries makes Emface (non-invasive facial lifting), Emsculpt, and Exilis - all sold to aesthetic practices for skin and body treatment. Its Emface facial toning device competes with ellacor for the 'no-surgery facial rejuvenation' patient segment.
• Venus Concept: Venus Concept sells Venus Viva, Venus Versa, and other energy-based aesthetic devices used for skin resurfacing and tightening in medical aesthetic practices. Its Viva fractional RF system competes directly with ellacor for skin rejuvenation cases.
• Solta Medical (Bausch Health): Solta Medical, a Bausch Health company, manufactures Thermage (RF skin tightening) and Fraxel (fractional laser), the legacy gold-standard skin rejuvenation devices in the same aesthetic practice channel as ellacor. Direct competitor for skin tightening and wrinkle reduction indications.

Emerging players

• Apyx Medical (Renuvion): Apyx Medical markets the Renuvion system for subdermal skin tightening using helium plasma technology. Its minimally invasive skin contraction approach overlaps with ellacor's positioning between non-invasive treatments and surgery, targeting the same plastic surgeon channel.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/cytrellis
• LinkedInlinkedin.com/company/cytrellis-biosystems-inc-
• Instagraminstagram.com/ellacorskin

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cytrellis Biosystems